Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: A retrospective, multicenter analysis

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 171-176

  Styler, M J ^a   Crilley, P ^a   Biggs, J ^b   Moul, J ^a   Copelan, E ^c   Topolsky, D ^a   Avalos, B ^c   Penza, S ^c   Sabol, P ^a   Downs, K ^b   Szer, J ^d,e   Brodsky, I ^a   Marks, D I ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b ST VINCENT S HOSPITAL   (Australia)

^c OHIO STATE UNIVERSITY   (United States)

^d ALFRED HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Bone marrow transplantation; Busulfan; Cyclophosphamide; Estrogen; Liver dysfunction; Progestins; Veno occlusive disease

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; ESTROGEN; GESTAGEN; METHOTREXATE; VANCOMYCIN;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; ESTROGENS; FEMALE; GENETIC DISEASES, INBORN; GRAFT VS HOST DISEASE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIFE TABLES; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; METHOTREXATE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; NEOPLASMS; PROGESTINS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; VANCOMYCIN;

EID: 9544245818     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-122.
2. Frickhofen N, Wiesneth M, Jainta C et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998-2004.
3. 1, for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990; 74: 277-281.
4. Essell JH, Thompson JM, Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1993; 79: 2784-2788.
5. Shulman HM, McDonald GB, Matthews D et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79: 1178-1191.
6. Shulman HM Hinterberger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
7. Jones RJ, Lee KSK, Beschorner WF et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
8. Carreras E, Granena A, Navasa M et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993; 66: 77-80.
9. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation, a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
10. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
11. Crilley P, Topolsky D, Bulova S et al. Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia. Bone Marrow Transplant 1990; 5: 187-191.
12. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone marrow transplantation group. Blood 1994; 83: 2723-2730.
13. Brodsky R, Topolsky D, Crilley P et al. Frequency of veno-occlusive disease of the liver in bone marrow trasnplantation with a modified busulfan/cyclophosphamide preparative regimen. Am J Clin Oncol 1990; 13: 221-225.
14. Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 839-843.
15. Morgan M, Dodds A, Atkinson K et al. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991; 77: 529-534.
16. Nevill TJ, Barnet MJ, Klingemann H-G et al. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991; 9: 1224-1232.
17. Baily S, Fay M, Roche Y. Effects of quinolones on tumor necrosis factor production by human monocytes. Int J Immunopharmacol 1990; 12: 31-36.
18. Bianco JA, Neumunaitis J, Andrews DF et al. Combined therapy with pentoxyfylline (PTX), ciprofloxacin (CIPRO) and prednisone (PD) reduces regimen related toxicity (RRT) and accelerates engraftment in patients undergoing bone marrow transplantation (BMT). Blood 1991; 78 (Suppl.): 237a.
19. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy 1993; 13: 4S-17S.
20. Shulman HN, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127: 549-555.
21. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J 1969; 2: 651-657.
22. Sartwell PE, Masi AT, Arthes FG et al. Thromboembolism and oral contraceptives: an epidemiological case control study. Am J Epidemiol 1969; 90: 365-380.
23. Poller L, Thomson JM, Thomas W. Oestrogen/progestogen oral contraception and blood clotting: a long term follow-up. Br Med J 1971; 4: 648-650.
24. Hougie C, Rutherford RW, Banks AL, Colvin WA. Effect of a progestin-estrogen oral contraceptive on blood coagulation. Metabolism 1965; 14: 411-417.
25. Panicucci F, Sagripanti A, Conte B et al. Anti-thrombin III, heparin cofactor and antifactor Xa in relation to age, sex and pathological condition. Hemostasis 1980; 9: 297-302.
26. Gilabert J, Fernandez JA, Espana F et al. Physiological coagulation inhibitors (protein C, protein S and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988; 49: 319-329.
27. Boerger LM, Morris PC, Thurnau GR et al. Oral contraceptives and gender affect protein S status. Blood 1987; 69: 692-694.
28. Setchell KD, Gosselin SJ, Welsh MB et al. Dietary estrogens - a probable cause of infertility and liver disease in captive cheetahs. Gastroenterology 1987; 93: 225-233.
29. Ganem G, Saint-Marc Gerardin M-F, Kuentz M et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Radiat Oncol Biol Phys 1988; 14: 879-884.
30. Bearman SI, Garnet AL, Mori M et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-1736.
31. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 11: 3005-3020.